Company: Verge Genomics
Conditions: ALS, Alzheimer’s disease, Parkinson’s disease
Mechanism Type: Computational analysis
Mechanism: Verge Genomics is applying network algorithms to large-scale gene expression data to map out clusters of co-regulated genes implicated in neurodegenerative diseases, including in ALS. They then examine publicly-available information to identify FDA-approved drugs that can be tested to affect the gene clusters of interest.
U.S. Status for ALS: Preclinical
 Verge Genomics Wants To Cure Neurodegenerative Diseases Through Advanced Algorithms. Crook, J. TechCruch, 21 Jul 2015. Accessed 11 Mar 2016 from http://techcrunch.com/2015/07/21/verge-genomics-wants-to-cure-neurodegenerative-diseases-through-advanced-algorithms/.
 A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. Chen, JA et al. JAMA Neurol. 2015 Apr;72(4):414-22.
Last updated March 11th, 2016